ArticleComplementary medicine research2026
Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Complementary medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFatigue is one of the most common symptoms of post-COVID syndrome. The Chinese herbal medicine Shengmai liquid has been recorded in ancient books, and modern studies have shown its ability to relieve fatigue. This study aims to assess the clinical efficacy and safety of Shengmai liquid in improving fatigue symptoms in post-COVID syndrome patients.
methodsWe plan to enroll 100 eligible patients with post-COVID-19 fatigue from Beijing Ditan Hospital, randomly allocating them into either the Shengmai liquid or placebo group. Blinding will be maintained for the personnel responsible for evaluating outcomes and performing statistical analysis. The participants will be treated for 8 weeks and followed for another 30 days. We utilized the modified Fatigue Impact Scale as our main endpoint to evaluate changes in patient fatigue. The secondary outcomes will include the Traditional Chinese Medicine Syndrome Score Scale, Hamilton Depression Inventory-17 items, Hamilton Anxiety Scale, Pittsburgh Sleep Quality Scale, World Health Organization Quality-of-Life Scale, and 6-min walk distance. All the statistical analyses will use SPSS software with a 0.05 significance level and follow the intention-to-treat principle.
conclusionThis randomized, single-center, double-blind trial will provide robust clinical evidence regarding the short-term efficacy and safety of Shengmai liquid for the treatment of post-COVID-19 fatigue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.